Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Soligenix (NASDAQ:SNGX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Risk and Volatility
Halozyme Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.
Earnings and Valuation
This table compares Halozyme Therapeutics and Soligenix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Halozyme Therapeutics | $1.40 billion | 8.23 | $316.89 million | $3.93 | 25.67 |
| Soligenix | $120,000.00 | 39.64 | -$11.08 million | ($0.98) | -0.33 |
Halozyme Therapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 1.9% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Halozyme Therapeutics and Soligenix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Halozyme Therapeutics | 26.93% | 751.81% | 23.84% |
| Soligenix | N/A | -165.32% | -97.40% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Halozyme Therapeutics and Soligenix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Halozyme Therapeutics | 2 | 3 | 7 | 1 | 2.54 |
| Soligenix | 1 | 0 | 0 | 0 | 1.00 |
Halozyme Therapeutics presently has a consensus price target of $108.18, suggesting a potential upside of 7.26%. Given Halozyme Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Soligenix.
Summary
Halozyme Therapeutics beats Soligenix on 13 of the 15 factors compared between the two stocks.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
About Soligenix
Soligenix, Inc. is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval. Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
